Home

Qualificazione Trascurare partire dara velcade dex protocol Irritato telecamera Per quanto riguarda le persone

DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts

Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma

41408_2022_653_MOESM1_ESM.mp4
41408_2022_653_MOESM1_ESM.mp4

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica

Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica

Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

New developments in the treatment of multiple myeloma--clinical utility of daratumumab - Document - Gale Academic OneFile
New developments in the treatment of multiple myeloma--clinical utility of daratumumab - Document - Gale Academic OneFile

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview SUPERSEDED | eviQ
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview SUPERSEDED | eviQ

PDF) Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
PDF) Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Pomalidomide and Dexamethasone (Pom-Dex) With or Without Daratumumab (DARA) in Patients (Pts) With Relapsed or Refractory Multi
Pomalidomide and Dexamethasone (Pom-Dex) With or Without Daratumumab (DARA) in Patients (Pts) With Relapsed or Refractory Multi

NCT02874742
NCT02874742

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma - ScienceDirect
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma - ScienceDirect

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate

PDF) Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
PDF) Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study | Haematologica
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study | Haematologica

DeRIVE Study - Emory University - Dara/Ixa/Dex Vs Dara/Vel/Dex - Multiple Myeloma Clinical Trials
DeRIVE Study - Emory University - Dara/Ixa/Dex Vs Dara/Vel/Dex - Multiple Myeloma Clinical Trials

Sashi Manthravadi (@smanthravadimd) / X
Sashi Manthravadi (@smanthravadimd) / X

Life | Free Full-Text | Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
Life | Free Full-Text | Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival | Annals of Hematology
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival | Annals of Hematology